A detailed history of Daiwa Securities Group Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 25,341 shares of ALLO stock, worth $62,338. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,341
Previous 26,360 3.87%
Holding current value
$62,338
Previous $61,000 16.39%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.08 - $3.5 $2,119 - $3,566
-1,019 Reduced 3.87%
25,341 $71,000
Q2 2024

Aug 07, 2024

SELL
$2.23 - $4.38 $9,316 - $18,299
-4,178 Reduced 13.68%
26,360 $61,000
Q1 2024

May 02, 2024

SELL
$2.92 - $5.63 $5,723 - $11,034
-1,960 Reduced 6.03%
30,538 $137,000
Q4 2023

Jan 31, 2024

BUY
$2.28 - $3.5 $39,833 - $61,148
17,471 Added 116.26%
32,498 $104,000
Q2 2023

Jul 31, 2023

BUY
$4.53 - $6.74 $65,648 - $97,676
14,492 Added 2708.79%
15,027 $75,000
Q2 2022

Aug 09, 2022

BUY
$6.78 - $12.28 $806 - $1,461
119 Added 28.61%
535 $6,000
Q4 2021

Feb 03, 2022

SELL
$13.13 - $24.52 $932 - $1,740
-71 Reduced 14.58%
416 $6,000
Q3 2021

Nov 05, 2021

BUY
$21.01 - $27.64 $4,370 - $5,749
208 Added 74.55%
487 $13,000
Q1 2021

May 03, 2021

BUY
$25.79 - $39.02 $386 - $585
15 Added 5.68%
279 $10,000
Q4 2020

Feb 04, 2021

SELL
$25.24 - $43.45 $13,200 - $22,724
-523 Reduced 66.45%
264 $7,000
Q3 2020

Nov 02, 2020

BUY
$32.38 - $44.96 $3,205 - $4,451
99 Added 14.39%
787 $30,000
Q4 2019

Jan 31, 2020

BUY
$24.82 - $31.4 $17,076 - $21,603
688 New
688 $18,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $354M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.